Tandem Diabetes Care (Nasdaq:TNDM) announced today that the FDA cleared its Tandem Mobi automated insulin delivery (AID) system. Clearance covers people with diabetes ages six and up, expanding the Tandem portfolio of products. San Diego-based Tandem says Mobi, which is fully controllable from a mobile app, is the world’s smallest durable AID system. Mobi features […]
Technology
Medicare now covers new Medtronic MiniMed 780G automated insulin pump
Medtronic (NYSE:MDT) announced today that Medicare now covers its new MiniMed 780G system with the Guardian 4 sensor. Coverage for the recently FDA-approved automated insulin delivery system extends to all eligible Medicare and Medicare Advantage beneficiaries. Medtronic intends to begin processing orders immediately. The company plans to start shipments to eligible recipients with type 1 […]
Insulin delivery tech developer Modular Medical names former Insulet CEO to board
Modular Medical (Nasdaq:MODD) announced today that it appointed industry veteran Duane DeSisto to its board of directors. DeSisto previously served as president, CEO and director of Insulet. He led the company as it developed the Omnipod insulin management system until his retirement in 2014. Modular Medical, a development-stage insulin delivery technology company, aims to launch […]
Study supports use of CamDiab artificial pancreas in pregnant women with type 1 diabetes
The CamDiab CamAPS FX automated insulin delivery (AID) system produced better outcomes for pregnant women with type 1 diabetes in a clinical study. Medscape reported that data came from the largest randomized controlled trial pitting an AID system against standard insulin delivery in pregnant women with type 1 diabetes. The automated CamAPS FX came out […]
Dexcom CCO Teri Lawver says new sensor is ‘first step’ to expand addressable market
Teri Lawver joined Dexcom (Nasdaq:DXCM) as chief commercial officer just as the company got set for a massive commercial undertaking. The FDA cleared the company’s next-generation Dexcom G7 continuous glucose monitor (CGM) in December 2022. One month later, Lawver assumed the position of CCO. Within about a month, she was set to oversee the U.S. launch […]
The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions
As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]
Ypsomed to expand drug delivery device manufacturing, add 200 jobs
Ypsomed announced today that, at its annual general meeting, its shareholders approved all proposals, including facility expansions. Burgdorf, Switzerland-based Ypsomed develops drug delivery devices, including insulin pumps for those with diabetes. Its YpsoPump represents a leading offering as an automated insulin delivery system compatible with certain software and glucose monitors. Board member Simon Michel confirmed […]
Study shows health equity impact from Virta Health diabetes reversal platform
Virta Health announced that real-world data for its diabetes reversal platform demonstrated narrowing gaps in care. The company shared its data at the American Diabetes Association’s 83rd Scientific Sessions. The research highlighted its impact on health equity. It demonstrated significant health improvement and medication reduction for members in the most and least disadvantaged U.S. neighborhoods. […]
Vida Health reports positive data for virtual diabetes program in low-income populations
Vida Health announced new research demonstrating significantly lowered A1C levels with its virtual cardiometabolic program. The research highlighted use of the program in low-income Medicare Advantage members. Significantly lowered A1C levels even occurred in areas with limited income and food access. Vida Health’s study compared its members living in areas of low income and low […]
Data supports safety and accuracy of Senseonics 365-day CGM
Senseonics (NYSE:SENS) today announced positive clinical data highlighting the effectiveness of its Eversense continuous glucose monitor (CGM). Germantown, Maryland-based Senseonics presented two studies on its latest-generation Eversense E3 at the American Diabetes Association 83rd Scientific Session. The 180-day implantable CGM received FDA approval in February of last year. The sensor is fully implantable and requires just […]